Jafernik Karolina, Motyka Sara, Calina Daniela, Sharifi-Rad Javad, Szopa Agnieszka
Chair and Department of Pharmaceutical Botany, Jagiellonian University, Medical College, Medyczna 9 St., 30-688, Kraków, Poland.
Doctoral School of Medical and Health Sciences, Medical College, Jagiellonian University, Łazarza 16 St., 31-530, Kraków, Poland.
Chin Med. 2024 Jan 24;19(1):17. doi: 10.1186/s13020-024-00879-0.
Cancer remains one of the leading causes of mortality worldwide. The search for novel and effective anticancer agents has been a significant area of research. Dibenzocyclooctadiene lignans (DBCLS), derived from the Schisandra genus plants like: S. chinensis, S. sphenanthera, S. henryi, S. rubriflora, S. grandiflora, S. propinqua, and S. glabra, have been traditionally used in various medicinal systems and are known for their myriad health benefits, including anticancer properties. This comprehensive review aimed to collate and critically analyse the recent literature on the anticancer properties of DBCLS, focusing on their mechanistic approaches against different cancer types. An exhaustive literature search was performed using databases like PubMed/MedLine, Scopus, Web of Science, Embase, TRIP database and Google Scholar from 1980 to 2023. Peer-reviewed articles that elucidated the mechanistic approach of these lignans on cancer cell lines, in vivo models and preliminary clinical studies were included. Studies were assessed for their experimental designs, cancer types studied, and the mechanistic insights provided. The studies demonstrate that the anticancer effects of DBCLS compounds are primarily driven by their ability to trigger apoptosis, arrest the cell cycle, induce oxidative stress, modulate autophagy, and disrupt essential signaling pathways, notably MAPK, PI3K/Akt, and NF-κB. Additionally, these lignans have been shown to amplify the impact of traditional chemotherapy treatments, suggesting their potential role as supportive adjuncts in cancer therapy. Notably, several studies also emphasise their capacity to target cancer stem cells and mitigate multi-drug resistance specifically. DBCLS from the Schisandra genus have showcased significant potential as anticancer agents. Their multi-targeted mechanistic approach makes them promising candidates for further research, potentially leading to developing of new therapeutic strategies in cancer management.
癌症仍然是全球主要的死亡原因之一。寻找新型有效的抗癌药物一直是一个重要的研究领域。二苯并环辛二烯木脂素（DBCLS）来源于五味子属植物，如：中华五味子、华中五味子、绿叶五味子、红花五味子、大花五味子、翅枝五味子和无毛五味子，传统上已在各种医学体系中使用，并因其众多的健康益处而闻名，包括抗癌特性。这篇综述旨在整理和批判性分析最近关于DBCLS抗癌特性的文献，重点关注其针对不同癌症类型的作用机制。使用PubMed/MedLine、Scopus、Web of Science、Embase、TRIP数据库和谷歌学术等数据库，对1980年至2023年的文献进行了详尽的检索。纳入了阐述这些木脂素对癌细胞系、体内模型和初步临床研究作用机制的同行评审文章。对研究的实验设计、所研究的癌症类型以及提供的作用机制见解进行了评估。研究表明，DBCLS化合物的抗癌作用主要由其触发细胞凋亡、阻滞细胞周期、诱导氧化应激、调节自噬以及破坏重要信号通路（尤其是MAPK、PI3K/Akt和NF-κB）的能力驱动。此外，这些木脂素已被证明可增强传统化疗的效果，表明它们在癌症治疗中作为辅助支持药物的潜在作用。值得注意的是，多项研究还强调了它们靶向癌症干细胞并特异性减轻多药耐药性的能力。五味子属的DBCLS已展现出作为抗癌药物的巨大潜力。它们的多靶点作用机制使其成为进一步研究的有希望的候选物，有可能在癌症治疗中开发出新的治疗策略。
